BDC operators have commenced discussions on mergers and acquisition (M&A) in order to meet the recapitalisation deadline set ...

The Central Bank of Nigeria (CBN) has waived N250,000 annual licence renewal fee for each Bureau De Change (BDC) operator for ...

The revised guidelines introduce new licensing requirements, categorize BDCs into Tier-1 and Tier-2 groups, and update the permissible activities, financial, corporate governance, and anti-money ...

Kura Oncology (KURA) and Kyowa Kirin announced topline results from KOMET-001, the Phase 2 registration-directed trial of ziftomenib, a highly ...

AML Incubator's new service offering provides FinTech firms with a practical solution to expand into and through Canada without being slowed by compliance complexities. For more information, visit our ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML ...

Acute myeloid leukaemia (AML) is mainly characterized by an increase in the number of myeloid cells in the bone marrow and a decrease in mature cells, accounting for 28% of leukaemia cases ...

Treosulfan plus fludarabine is approved for alloHSCT in patients with AML or MDS aged 1 year and older. Clinical trial results showed improved overall survival with treosulfan compared to busulfan.

In part 1 of this interview, Sekeres discussed the data leading to treosulfan's approval for patients 1 year and older with AML or MDS ahead of allo-HSCT. This transcript has been lightly edited ...

The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan ... aged 1 year and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Findings showed OS ...

Opens in a new tab or window The FDA approved treosulfan (Grafapex ... patients ages 1 year and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), Medexus announced ...